Furthermore, we tested the suitability of 14 as a molecular tool for future fragment-based drug discovery/screening approaches. As fragment screening is usually associated with high compound concentrations and thus high amounts of DMSO as a co-solvent, we first investigated the DMSO tolerance of our NanoBRET-based CCR2 binding assay. Therefore, Ki values for 4 were determined at different concentrations of DMSO.